Amgen Inc. (SNSE:AMGN)
Chile · Delayed Price · Currency is CLP · Price in USD | Market Cap | 159.60T +12.8% |
| Revenue (ttm) | 34.61T +9.1% |
| Net Income | 7.25T +31.5% |
| EPS | 13,359.54 +31.3% |
| Shares Out | n/a |
| PE Ratio | 22.01 |
| Forward PE | 14.61 |
| Dividend | 8,965.01 (2,693.97%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 332.78 |
| Day's Range | n/a |
| 52-Week Range | 246.21 - 377.05 |
| Beta | n/a |
| RSI | 100.00 |
| Earnings Date | Apr 30, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 7, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 10:00 a.m.
Amgen upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded Amgen (AMGN) to Buy from Hold with an unchanged price target of $375. Amgen’s Q1 results were “fully in line with our expectations, although the quarter is
Amgen downgraded to Hold from Buy at Erste Group
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy.
Erste downgrades Amgen on declining sales growth
Erste Group analyst Hans Engel downgraded Amgen (AMGN) to Hold from Buy, saying the company’s sales growth will likely decline in 2026 and 2027. Amgen’s growth is lower than competitors,
Amgen to invest additional $300M in U.S. manufacturing network
Amgen (AMGN) announced plans to invest an additional $300M in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a relia...
Amgen to invest additional $300 million to boost US manufacturing footprint
Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S. manufacturing network.
AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to i...
Amgen price target lowered to $340 from $351 at Guggenheim
Guggenheim lowered the firm’s price target on Amgen (AMGN) to $340 from $351 and keeps a Neutral rating on the shares. The firm is updating its model following the company’s
Amgen price target raised to $307 from $304 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $307 from $304 and keeps an Underperform rating on the shares. The firm, which adjusted estimates in-line with recent launch
Amgen price target raised to $332 from $326 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Amgen (AMGN) to $332 from $326 and keeps an Equal Weight rating on the shares. Amgen posted an in-line Q1 on revenue,
Amgen price target raised to $327 from $325 at Truist
Truist raised the firm’s price target on Amgen (AMGN) to $327 from $325 and keeps a Hold rating on the shares after its inline Q1 results for revenue and a
Amgen raises FY26 adjusted EPS view to $21.70-$23.10 from $21.60-$23.00
FY26 consensus $22.32. Raises FY26 revenue view to $37.1B-$38.5B from $37B-$38.4B, consensus $37.79B.
Amgen Earnings Call Transcript: Q1 2026
Strong Q1 results driven by 24% growth in key products offsetting legacy declines, with raised 2026 guidance for revenue and EPS. Pipeline advances in obesity, rare disease, and oncology, plus AI integration, support long-term growth.
Amgen Posts Higher First-Quarter Profit, Revenue
The biotechnology company reported a profit of $1.82 billion, driven by a 4% rise in product sales.
Amgen reports Q1 adjusted EPS $5.15, consensus $4.77
Reports Q1 revenue $8.6B, consensus $8.57B. “Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected pate...
Amgen sees FY26 CapEx $2.6B; share repurchases not to exceed $3B
16:03 EDT Amgen (AMGN) sees FY26 CapEx $2.6B; share repurchases not to exceed $3B
Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
Amgen on Thursday reported first-quarter product sales rose 4%, helped by demand for cholesterol and rare disease medicines, and said it was moving forward with a broad development program for exper...
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.
FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development
The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results to accelerate the time frame it takes to develop
FDA proposes to withdraw Amgen's rare autoimmune disease drug
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a lack of ...
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 24, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of t...
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
Organizational Changes Further Emphasize Integration of Biology and Technology THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M.
Amgen's lung cancer drug tarlatamab wins China approval
Amgen's lung cancer drug tarlatamab has won approval from China's National Medical Products Administration, its development and commercialisation partner BeOne Medicines said on Friday on WeChat.